NFATc3 is required for chronic hypoxia-induced pulmonary hypertension in adult and neonatal mice
about
Mechanisms of Vascular Smooth Muscle Contraction and the Basis for Pharmacologic Treatment of Smooth Muscle DisordersEnhanced depolarization-induced pulmonary vasoconstriction following chronic hypoxia requires EGFR-dependent activation of NAD(P)H oxidase 2Selective and strain-specific NFAT4 activation by the Toxoplasma gondii polymorphic dense granule protein GRA6.Mechanisms of NFATc3 activation by increased superoxide and reduced hydrogen peroxide in pulmonary arterial smooth muscle.MicroRNA-124 suppresses the transactivation of nuclear factor of activated T cells by targeting multiple genes and inhibits the proliferation of pulmonary artery smooth muscle cellsThe α and Δ isoforms of CREB1 are required to maintain normal pulmonary vascular resistance.Amniotic fluid RNA gene expression profiling provides insights into the phenotype of Turner syndrome.Galangin attenuates airway remodelling by inhibiting TGF-β1-mediated ROS generation and MAPK/Akt phosphorylation in asthmaIGF-1 signaling in neonatal hypoxia-induced pulmonary hypertension: Role of epigenetic regulation.NFATc3 and VIP in Idiopathic Pulmonary Fibrosis and Chronic Obstructive Pulmonary DiseaseNFAT is required for spontaneous pulmonary hypertension in superoxide dismutase 1 knockout mice.ASIC1-mediated calcium entry stimulates NFATc3 nuclear translocation via PICK1 coupling in pulmonary arterial smooth muscle cellsReactive oxygen species in pulmonary vascular remodeling.Transcription factors, transcriptional coregulators, and epigenetic modulation in the control of pulmonary vascular cell phenotype: therapeutic implications for pulmonary hypertension (2015 Grover Conference series).Vascular smooth muscle cell phenotype is defined by Ca2+-dependent transcription factors.Recent advances in late lung development and the pathogenesis of bronchopulmonary dysplasia.Lung Circulation.The role of nuclear factor of activated T cells in pulmonary arterial hypertension.Soluble Epoxide Hydrolase Inhibition Protected against Angiotensin II-induced Adventitial RemodelingCalcineurin/NFAT Activation-Dependence of Leptin Synthesis and Vascular Growth in Response to Mechanical StretchPri-microRNA-124 rs531564 polymorphism minor allele increases the risk of pulmonary artery hypertension by abnormally enhancing proliferation of pulmonary artery smooth muscle cells.Enhanced NO-dependent pulmonary vasodilation limits increased vasoconstrictor sensitivity in neonatal chronic hypoxia.Altered Redox Balance in the Development of Chronic Hypoxia-induced Pulmonary Hypertension.Role of Transcription Factors in Pulmonary Artery Smooth Muscle Cells: An Important Link to Hypoxic Pulmonary Hypertension.NFAT regulation of cystathionine γ-lyase expression in endothelial cells is impaired in rats exposed to intermittent hypoxia.Central role of T helper 17 cells in chronic hypoxia-induced pulmonary hypertension.NFATc3 pathway participates in the process that 15-LO/15-HETE protects pulmonary artery smooth muscle cells against apoptosis during hypoxia.Pulmonary arterial wall thickness in Eisenmenger Syndrome: Prospective, cross-sectional, controlled clinical trial.Antenatal hypoxia and pulmonary vascular function and remodeling.
P2860
Q26753129-71AD3809-BDEB-4801-9699-A9A30AA37729Q28582157-4C223C2D-96D9-4062-885E-4AAB545FB393Q34230563-253443DA-347A-48DF-80F5-9E256B28492EQ34519078-693376BF-6CCC-44DF-BB8A-76D65CF9C38DQ34818972-D01D685B-B0A0-43A6-BF16-22B66F7C9C75Q35069403-69FB5FE0-04B0-4C86-AB36-2EFE2965639DQ35260595-EC56E9CB-243C-4733-9D14-666BE82AAD8BQ35834096-B1324E19-F1A0-476A-8CC6-F6A1C54CFFE4Q36083412-B0EA4118-C2E0-43C7-824E-8373F7F00AFEQ36261127-6F835E31-BCF7-4518-89DA-12FCECCE2885Q36837739-AEB2874E-E15D-4C1A-B4CD-7168832D7662Q37139574-0E9DDD20-0881-4E11-933B-2B0025FDB255Q37532988-78AEB294-EE72-4231-9E9E-AF8F085AB6C3Q37555457-20A92BC4-39D2-4A9E-97AC-3B3726D53404Q38121164-3B93DA58-DD3B-484D-A609-655EFD8BD267Q38161431-E63913A3-7777-48E7-B4BB-177A123CAFA7Q38804579-1EB84EEA-2A8E-494E-A678-E165CE714102Q39095141-7B4829E9-FCAB-4914-B3EB-F6839CF44D5EQ41191530-845F9567-CBC6-4651-9631-A31ABFEAC11DQ41211026-1C15F586-86BC-4267-9A0B-16E471D3F349Q42179558-EB27E3E1-F87A-43D8-A623-9D34FF2F6149Q42512749-D2743FBA-6AF0-43E5-95E4-984CB7EC3BC7Q46280877-F24A862C-F18D-460C-B6DE-CFFE93DA2FE0Q46280906-F1DC70D3-90E1-4781-9516-4FA946E4D6BDQ47769953-133013E1-C500-4938-85DD-4A5BA64511D9Q51132724-00BCC0E9-A072-4EE5-AF9F-E929A3C4D228Q51722031-7DA0FA82-AD63-4A94-8A6D-3FD6FE28337EQ53835942-C0AE6175-A23C-454E-BFF1-594FFBED4598Q55110701-9BE2AFC0-4D18-425B-8BAB-3AD5C4969FDC
P2860
NFATc3 is required for chronic hypoxia-induced pulmonary hypertension in adult and neonatal mice
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
NFATc3 is required for chronic ...... ion in adult and neonatal mice
@ast
NFATc3 is required for chronic ...... ion in adult and neonatal mice
@en
type
label
NFATc3 is required for chronic ...... ion in adult and neonatal mice
@ast
NFATc3 is required for chronic ...... ion in adult and neonatal mice
@en
prefLabel
NFATc3 is required for chronic ...... ion in adult and neonatal mice
@ast
NFATc3 is required for chronic ...... ion in adult and neonatal mice
@en
P2093
P2860
P1476
NFATc3 is required for chronic ...... ion in adult and neonatal mice
@en
P2093
J A Dominguez-Bautista
J Friedman
L V Gonzalez Bosc
S Codianni
S de Frutos
T A Howard
P2860
P304
P356
10.1152/AJPLUNG.00405.2010
P577
2011-09-09T00:00:00Z